Abstract:Abstract Oral squamous cell carcinoma (OSCC) is a prevalent form of cancer that develops in the oral cavity, globally recognized as the eighth most commonly diagnosed cancer. Despite the application of standard surgical techniques or concurrent chemoradiotherapy, the prognosis for OSCC patients remains unsatisfactory. Initially, cisplatin, the primary and most frequently used chemotherapy agent for treating OSCC, demonstrates effectiveness in therapy. Nonetheless, chemoresistance frequently arises, leading to treatment failure, and this is intricately associated with the activation of hypoxia-inducible factor 1α (HIF-1α) signaling. Recent research has brought to light heightened levels of HIF-1α-mediated vascular endothelial growth factor (VEGF) and BCL-2 in OSCC tumor sites, which play crucial roles in regulating angiogenesis and anti-apoptotic processes within cancer cells. Additionally, interventions aimed at targeting anti-apoptotic molecules or augmenting the expression of pro-apoptotic molecules may represent promising strategies to overcome chemoresistance in OSCC. Therefore, HIF-1α/VEGF/BCL-2 axis could be considered a potential target for the development of chemopreventive and chemotherapeutic strategies for OSCC. Lenvatinib is a targeted multi-kinase inhibitor that can inhibit tumor growth and angiogenesis by blocking the activation of vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptor (PDGFR) α, as well as the proto-oncogenes RET and KIT. However, whether lenvatinib may sensitizes OSCC to cisplatin remains unclear. In our study, we used the MTT assay to prove the cytotoxicity of OSCC cells (SAS and MOC1 cells) was induced by cisplatin and lenvatinib. We employed flow cytometry to verify that the combination of lenvatinib and cisplatin can indeed trigger both extrinsic and intrinsic apoptotic pathways in OSCC cells. Furthermore, our demonstration revealed that the induction of apoptosis pathways by the combination of lenvatinib and cisplatin is associated with mitochondrial-dependent apoptosis and death receptor-dependent apoptosis. Then, transwell invasion and migration assay results proved the inhibition effect of lenvatinib combined with cisplatin in SAS and MOC1 cells. Furthermore, we indicated that the combination of lenvatinib and cisplatin can effectively inhibit angiogenesis and anti-apoptotic mechanisms mediated by the HIF-1α/VEGF/BCL-2 axis in OSCC cells. In summary, our results demonstrate that the combined treatment with lenvatinib and cisplatin enhances the response of OSCC cells under hypoxic conditions. Additionally, it aims to mitigate the negative impact of hypoxia on cisplatin's therapeutic effectiveness and increase the sensitivity of OSCC cells to cisplatin. Citation Format: Ying-Tzu Chen, Yan-Ting Tsai, Fei-Ting Hsu, Hsi-Feng Tu. Evaluate the potential sensitization effect and underlying mechanism of lenvatinib on cisplatin resistance oral squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4736.

VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells

The Identification of the ATR Inhibitor VE-822 As a Therapeutic Strategy for Enhancing Cisplatin Chemosensitivity in Esophageal Squamous Cell Carcinoma

The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin

Effects of TRAIL combined with cisplatin on Hep-2 laryngeal squamous carcinoma in vitro

VE-822 Mediated Inhibition of ATR Signaling Sensitizes Chondrosarcoma to Cisplatin Via Reversion of the DNA Damage Response

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Cisplatin Plus Anti-Pd-1 Antibody Enhanced Treatment Efficacy in Advanced Esophageal Squamous Cell Carcinoma.

Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma

BEZ235 reduction of cisplatin resistance on wild-type EGFR non-small cell lung cancer cells

[Combination of Cytosine Arabinoside and Cisplatin Enhances Inhibition of Cell Proliferation and Promotes Apoptosis of Resistant Nasopharyngeal Carcinoma Cells].

All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer

Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer

Ott_a_211560 6083..6092

Abstract 4736: Evaluate the potential sensitization effect and underlying mechanism of lenvatinib on cisplatin resistance oral squamous cell carcinoma

The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

Antitumor effects of recombinant quail vascular endothelial growth factor receptor 2, as a vaccine, combined with cisplatin on LL/2 tumor model in mice]

Inhibition of Wee1 Sensitizes AML Cells to ATR Inhibitor VE-822-induced DNA Damage and Apoptosis.

Combined Effects of Octreotide and Cisplatin on the Proliferation of Side Population Cells from Anaplastic Thyroid Cancer Cell Lines